[1] 李杰,陈杰,庄辉. 丙型肝炎的流行病学.实用肝脏病杂志,2012,15(5):379-380. [2] 中华医学会肝病学分会,中华医学会传染病与寄生虫病学分会.丙型肝炎防治方案. 中华肝脏病杂志,2004,12(4):194. [3] 中华医学会肝病学分会,中华医学会传染病与寄生虫病学分会.丙型肝炎防治方案. 中华传染病杂志,2004,22(2):133. [4] 曹国庆,倪家骧.高压臭氧自体血回输疗法的临床应用及护理体会. 临床合理用药杂志,2011,4(4):102. [5] Ghany MG,Strader DB,Thomas DL,et al. Diagnosis,management,and treatment of hepatitis C:an update. Hepatology,2009,49(4):1335-1374. [6] McCaughan GW,Omata M,Amarapurkar D,et al.Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis,management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol,2007,22(5):615-633. [7] Ferenci P,Fried MW,Shiffman MI,et al. Prediction sustained virological responses in chronic hepatitis C patients treated with peginterferon-2a(40 KD)/ribavirin. J Hepatol,2005,43(3):425-433. [8] Bressler BL,Guindi M,Tomlinson G,et a1. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology,2003,38:639-644. [9] Elgouhari HM,Zein CO,Hanouneh I,et al. Diabetes mellitus is associated with impaired response to antiviral therapy in chronic hepatitis C infection. Dig Dis Sci,2009,54(12):2699-2705. [10] Pingyun T,chungien Y,Yichin L,et a1.Associaion between abnormal liver function and risk factors for metabolic syndrome among freshman.J Adolescent Health,2007,41:132-137. [11] Fried MW,Hadziyannis SJ.Treatment of chronic hepatitis C:a system review.Hepatology,2002,36(5):S135-S144. [12] 魏来. 我国丙型肝炎抗病毒治疗现状与小分子药物的应用前景. 中华肝脏病杂志,2013,21(6):403-405. [13] 阿米娜·依明,铁木尔·玉努斯,丽娜. 聚乙二醇干扰素a-2a和利巴韦林联合治疗慢性丙型肝炎临床观察.实用肝脏病杂志,2011,14(6):453. [14] Larini A,Bocci V.Effects of ozone on isolated peripheral blood mononuclear cells.Toxicol In Vitro,2005,19(1):55-61. [15] 霍荻,杨运赢,敷飞贺,等. 医用三氧与中药对醋氨酚犬中毒的保护作用. 世界华人消化杂志,2007,15(3):282. [16] 黄长形,白雪帆. 慢性丙型病毒性肝炎抗病毒治疗的不良反应及其处理. 中华传染病杂志,2006,24(3):212. |